Melanoma Clinical Trials

Showing 881-900 of 1,477 trials

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

NCT02902042

This study will investigate the influence of maintenance therapy on progression-free survival (PFS) and overall survival (OS) after combination therapy with BRAF/MEK (MAP-ERK kinase) inhibitors and PD-1 antibody pembrolizumab. In the safety phase I part the optimal dose of pembrolizumab in combination with BRAF inhibitor and MEK inhibitor and the safety of this three-drugs-combination regime will be determined. In the randomized part 2 different maintenance therapies will be tested for toxicity and efficacy. Patients with disease control after 6 months of triple therapy will be randomized to receive 2 different maintenance therapies further on, either continuation of triple therapy or administration of pembrolizumab alone.

Malignant Melanoma

Prof. Dr. med. Dirk Schadendorf16 participantsStarted Apr 2018

Freiburg im Breisgau, Baden-Wurttemberg, Germany • Augsburg, Bavaria, Germany • München, Bavaria, Germany +8 more locations

UNKNOWNPhase 2

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

NCT04749485

HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the efficacy and safety of HX008 in patients with locally advanced or metastatic melanoma who have failed the standard treatments will be evaluated.

Melanoma

Taizhou Hanzhong biomedical co. LTD119 participantsStarted Nov 2018

Beijing, Beijing Municipality, China • Fuzhou, Fujian, China • Guangzhou, Guangdong, China +8 more locations

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

A Study of HX008 for the Treatment of Patients With Malignant Melanoma

Related Searches

Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor.

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma

Trial of pIL-12/MK-3475 in Metastatic Melanoma

Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm

Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Passive Versus Active Educational Interventions for Melanoma Recognition